MPM BioImpact’s Cytokinetics CYTK Stock Holding History

MPM BioImpact’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-500,000	Closed	-$33M	–	42
2026 Q1	$33M	Buy	+500,000	New	+$31.8M	2.55%	16
2022 Q4	–	Sell	-193,205	Closed	-$9.36M	–	37
2022 Q3	$9.36M	Sell	193,205 -1,041	-0.5%	-$50.1K	2.22%	14
2022 Q2	$7.63M	Sell	194,246 -30,000	-13%	-$1.21M	2.12%	11
2022 Q1	$8.25M	Sell	224,246 -8,022	-3%	-$285K	2.22%	12
2021 Q4	$10.6M	Sell	232,268 -15,023	-6%	-$580K	1.93%	13
2021 Q3	$8.84M	Buy	+247,291	New	+$7.28M	1.37%	17

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MPM BioImpact's CYTK Position: Q2 2026 in Review

MPM BioImpact sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 500,000 shares — an estimated $33M sold.

MPM BioImpact first reported a position in CYTK in Q3 2021 and held it in 6 quarters. The position peaked at $33M in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

MPM BioImpact reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
MPM BioImpact sold 500,000 Cytokinetics shares in Q2 2026, an estimated $33M.
MPM BioImpact first reported a position in Cytokinetics in Q3 2021 and held it in 6 quarters.
MPM BioImpact's Cytokinetics position peaked at $33M in Q1 2026.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.